Ghent University Academic Bibliography

Advanced

Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update

Helen Van Hoecke UGent, Liesbet Vandenbulcke UGent and Paul Van Cauwenberge (2007) DRUGS. 67(18). p.2717-2726
abstract
Allergic rhinitis represents a global health burden. The disease can seriously affect quality of life and is associated with multiple co-morbidities. Histamine and leukotrienes are important pro-inflammatory mediators in nasal allergic inflammation. Their actions on target cells are mediated through specific receptors and, consequently, molecules that block the binding of histamine and leukotrienes to their receptors have been important areas of pharmacological research. The published literature of the pathophysiology of histamine and leukotrienes, and the effects of histamine H(1)receptor antagonists (H-1 antihistamines) and leukotriene antagonists in monotherapy or in combination therapy in the treatment of allergic rhinitis was reviewed. The presented results are based on the best available evidence. The efficacy of H-1 antihistamines and leukotriene antagonists (montelukast in particular) in allergic rhinitis has been established in numerous randomised placebo-controlled trials. Results from meta-analyses indicate that H-1 antihistamines and leukotriene antagonists are equally effective in improving symptoms of allergic rhinitis and quality of life, but that both drugs are less effective than intranasal corticosteroids. Data on the combination of H-1 antihistamines and leukotriene antagonists in allergic rhinitis are limited. The available evidence shows that a combined mediator inhibition has additional benefits over the use of each agent alone, but is still inferior to intranasal corticosteroids. More well designed studies are needed to fully understand the benefits of a concomitant use of these agents.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
SODIUM CROMOGLYCATE, FEXOFENADINE HYDROCHLORIDE 120, NASAL SPRAY, DOUBLE-BLIND, RANDOMIZED CONTROLLED-TRIALS, INFLAMMATORY MEDIATORS, PLACEBO, PLUS CETIRIZINE, POLLEN EXPOSURE, MONTELUKAST
journal title
DRUGS
Drugs
volume
67
issue
18
pages
2717 - 2726
Web of Science type
Review
Web of Science id
000252178500005
JCR category
TOXICOLOGY
JCR impact factor
3.726 (2007)
JCR rank
8/72 (2007)
JCR quartile
1 (2007)
ISSN
0012-6667
language
English
UGent publication?
yes
classification
A1
id
390765
handle
http://hdl.handle.net/1854/LU-390765
date created
2008-03-04 08:33:00
date last changed
2016-12-19 15:43:01
@article{390765,
  abstract     = {Allergic rhinitis represents a global health burden. The disease can seriously affect quality of life and is associated with multiple co-morbidities. Histamine and leukotrienes are important pro-inflammatory mediators in nasal allergic inflammation. Their actions on target cells are mediated through specific receptors and, consequently, molecules that block the binding of histamine and leukotrienes to their receptors have been important areas of pharmacological research. 
The published literature of the pathophysiology of histamine and leukotrienes, and the effects of histamine H(1)receptor antagonists (H-1 antihistamines) and leukotriene antagonists in monotherapy or in combination therapy in the treatment of allergic rhinitis was reviewed. The presented results are based on the best available evidence. 
The efficacy of H-1 antihistamines and leukotriene antagonists (montelukast in particular) in allergic rhinitis has been established in numerous randomised placebo-controlled trials. Results from meta-analyses indicate that H-1 antihistamines and leukotriene antagonists are equally effective in improving symptoms of allergic rhinitis and quality of life, but that both drugs are less effective than intranasal corticosteroids. 
Data on the combination of H-1 antihistamines and leukotriene antagonists in allergic rhinitis are limited. The available evidence shows that a combined mediator inhibition has additional benefits over the use of each agent alone, but is still inferior to intranasal corticosteroids. More well designed studies are needed to fully understand the benefits of a concomitant use of these agents.},
  author       = {Van Hoecke, Helen and Vandenbulcke, Liesbet and Van Cauwenberge, Paul},
  issn         = {0012-6667},
  journal      = {DRUGS},
  keyword      = {SODIUM CROMOGLYCATE,FEXOFENADINE HYDROCHLORIDE 120,NASAL SPRAY,DOUBLE-BLIND,RANDOMIZED CONTROLLED-TRIALS,INFLAMMATORY MEDIATORS,PLACEBO,PLUS CETIRIZINE,POLLEN EXPOSURE,MONTELUKAST},
  language     = {eng},
  number       = {18},
  pages        = {2717--2726},
  title        = {Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update},
  volume       = {67},
  year         = {2007},
}

Chicago
Van Hoecke, Helen, Liesbet Vandenbulcke, and Paul Van Cauwenberge. 2007. “Histamine and Leukotriene Receptor Antagonism in the Treatment of Allergic Rhinitis: An Update.” Drugs 67 (18): 2717–2726.
APA
Van Hoecke, H., Vandenbulcke, L., & Van Cauwenberge, P. (2007). Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update. DRUGS, 67(18), 2717–2726.
Vancouver
1.
Van Hoecke H, Vandenbulcke L, Van Cauwenberge P. Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update. DRUGS. 2007;67(18):2717–26.
MLA
Van Hoecke, Helen, Liesbet Vandenbulcke, and Paul Van Cauwenberge. “Histamine and Leukotriene Receptor Antagonism in the Treatment of Allergic Rhinitis: An Update.” DRUGS 67.18 (2007): 2717–2726. Print.